OncRef

Clinical Trial: NCT05169567

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-10-06

Study Overview

Brief Summary

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Official Title

postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy

Conditions

Breast Neoplasm, Neoplasm Metastasis

Intervention / Treatment

  • Drug: Abemaciclib
  • Drug: Fulvestrant
  • Drug: Placebo

Other Study ID Numbers

  • 18238
  • I3Y-MC-JPEF
  • 2021-002301-10
  • 2023-506771-10-00
  • 2023

Start Date (Actual)

2022-03-11

Primary Completion Date (Actual)

2024-02-08

Study Completion Date (Estimated)

2027-12

Enrollment (Actual)

368

Study Type

Interventional

Phase

Phase 3